A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

Penelope G. Foulds, Peter Diggle, J. Douglas Mitchell, Angela Parker, Masato Hasegawa, Masami Masuda-Suzukake, David M A Mann, David Allsop

Research output: Contribution to journalArticle

Abstract

There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

Original languageEnglish (US)
Article number2540
JournalScientific Reports
Volume3
DOIs
StatePublished - Aug 29 2013
Externally publishedYes

Fingerprint

Synucleins
Parkinson Disease
Longitudinal Studies
Biomarkers

ASJC Scopus subject areas

  • General

Cite this

Foulds, P. G., Diggle, P., Mitchell, J. D., Parker, A., Hasegawa, M., Masuda-Suzukake, M., ... Allsop, D. (2013). A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease. Scientific Reports, 3, [2540]. https://doi.org/10.1038/srep02540

A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease. / Foulds, Penelope G.; Diggle, Peter; Mitchell, J. Douglas; Parker, Angela; Hasegawa, Masato; Masuda-Suzukake, Masami; Mann, David M A; Allsop, David.

In: Scientific Reports, Vol. 3, 2540, 29.08.2013.

Research output: Contribution to journalArticle

Foulds, PG, Diggle, P, Mitchell, JD, Parker, A, Hasegawa, M, Masuda-Suzukake, M, Mann, DMA & Allsop, D 2013, 'A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease', Scientific Reports, vol. 3, 2540. https://doi.org/10.1038/srep02540
Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M et al. A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease. Scientific Reports. 2013 Aug 29;3. 2540. https://doi.org/10.1038/srep02540
Foulds, Penelope G. ; Diggle, Peter ; Mitchell, J. Douglas ; Parker, Angela ; Hasegawa, Masato ; Masuda-Suzukake, Masami ; Mann, David M A ; Allsop, David. / A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease. In: Scientific Reports. 2013 ; Vol. 3.
@article{16739792d9ab42f38d738f11cc31cea0,
title = "A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease",
abstract = "There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.",
author = "Foulds, {Penelope G.} and Peter Diggle and Mitchell, {J. Douglas} and Angela Parker and Masato Hasegawa and Masami Masuda-Suzukake and Mann, {David M A} and David Allsop",
year = "2013",
month = "8",
day = "29",
doi = "10.1038/srep02540",
language = "English (US)",
volume = "3",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

AU - Foulds, Penelope G.

AU - Diggle, Peter

AU - Mitchell, J. Douglas

AU - Parker, Angela

AU - Hasegawa, Masato

AU - Masuda-Suzukake, Masami

AU - Mann, David M A

AU - Allsop, David

PY - 2013/8/29

Y1 - 2013/8/29

N2 - There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

AB - There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

UR - http://www.scopus.com/inward/record.url?scp=84902894449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902894449&partnerID=8YFLogxK

U2 - 10.1038/srep02540

DO - 10.1038/srep02540

M3 - Article

VL - 3

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 2540

ER -